DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers

Recruiting

Phase 2

BI 764532DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers

Sponsor:

Boehringer Ingelheim

Code:

NCT05882058

Conditions

Small Cell Lung Carcinoma

Neuroendocrine Neoplasms

Extra-pulmonary Neuroendocrine Carcinoma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

BI 764532, dose 1

BI 764532, dose 2

Ventana DLL3 RxDx assay

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-08-19. This information was provided to ClinicalTrials.gov by Boehringer Ingelheim on 2026-07-23.